02 October 2021>: Clinical Research
Preoperative Alkaline Phosphatase-to-Cholesterol Ratio as a Predictor of Overall Survival in Pancreatic Ductal Adenocarcinoma Patients Undergoing Radical Pancreaticoduodenectomy
Guotong Qiu ABCDEF , Lipeng Zhang BD , Zongting Gu CD , Hu Ren BC , Yongxing Du DF , Zongze Li B , Chengfeng Wang DFG*DOI: 10.12659/MSM.931868
Med Sci Monit 2021; 27:e931868
Table 1 Baseline characteristics of 102 pancreatic ductal adenocarcinoma patients who underwent radical pancreaticoduodenectomy, n (%).
Characteristic | Patients (n=102) |
---|---|
Age (year) | 59 (31–77) |
>60 | 44 (43.1) |
≤60 | 58 (56.9) |
Sex | |
Male | 47 (46.8) |
Female | 55 (53.9) |
Body mass index (kg/m) | 22.3 (17.4–31.9) |
>26.8 | 14 (13.7) |
≤26.8 | 88 (86.3) |
White blood cell (10/L) | 5.7 (2.8–25.8) |
>4.33 | 86 (84.3) |
≤4.33 | 16 (15.7) |
Alanine aminotransferase (U/L) | 68.5 (9.0–805.0) |
>15.55 | 89 (87.3) |
≤15.55 | 13 (12.7) |
Aspartate aminotransferase (U/L) | 53 (10.0–868.0) |
>25.5 | 74 (72.5) |
≤25.5 | 28 (27.5) |
Total bilirubin (umol/L) | 59.8 (3.6–419.5) |
>141.4 | 35 (34.3) |
≤141.4 | 67 (65.7) |
Albumin (g/L) | 40.6 (23.2–53.1) |
>40.55 | 52 (50.8) |
≤40.55 | 50 (49.2) |
Globulin (g/L) | 25.3 (1.9–209.0) |
>25.05 | 59 (57.8) |
≤25.05 | 43 (42.2) |
Carbohydrate antigen 19-9 (U/ml) | 189.5 (1.0–4839.0) |
>117.95 | 70 (68.6) |
≤117.95 | 32 (31.4) |
Clinical symptoms | |
Absent | 14 (13.7) |
Present | 88 (86.3) |
Diabetes | |
Absent | 75 (73.5) |
Present | 27 (26.5) |
Hypertension | |
Absent | 81 (79.4) |
Present | 21 (20.6) |
Smoking status | |
Absent | 69 (67.6) |
Present | 33 (32.4) |
Alcohol consumption | |
Absent | 76 (74.6) |
Present | 16 (15.7) |
Family history of cancer | |
Absent | 99 (97.1) |
Present | 3 (2.9) |
ASA | |
1 | 2 (2.0) |
2 | 84 (82.4) |
3 | 16 (15.7) |
Degree of differentiation | |
Poorly | 11 (10.8) |
Moderately | 85 (83.3) |
Well | 6 (5.9) |
Lymphovascular invasion | |
Absent | 65 (63.7) |
Present | 37 (36.3) |
Perineural invasion | |
Absent | 20 (19.6) |
Present | 82 (80.4) |
Capsular invasion | |
Absent | 30 (29.4) |
Present | 72 (70.6) |
Maximum tumor diameter (cm) | |
>4 | 14 (13.7) |
≤4 | 88 (86.3) |
T stage | |
T1 | 15 (14.7) |
T2 | 73 (71.6) |
T3 | 14 (13.7) |
N stage | |
N0 | 53 (52) |
N1 | 33 (32.4) |
N2 | 16 (15.7) |
TNM stage | |
1 | 41 (40.2) |
2 | 45 (44.1) |
3 | 16 (15.7) |
Adjuvant therapy | |
Absent | 49 (48) |
Present | 53 (52) |
Preoperative plasma alkaline phosphatase (U/L) | 207.0 (43.0–1385.0) |
>108.5 | 72 (70.6) |
≤108.5 | 30 (29.4) |
Preoperative plasma cholesterol (mmol/L) | 4.7 (2.3–12.5) |
>3.49 | 80 (78.4) |
≤3.49 | 22 (21.6) |
Preoperative ACR | 45.0 (9.0–325.9) |
>32.988 | 68 (66.7) |
≤32.988 | 34 (33.3) |
ACR – alkaline phosphatase/cholesterol ratio. |